06.19.15
Mission Pharmacal has acquired the assets of ProSolus Pharmaceuticals LP headquartered in Miami, FL. ProSolus offers expertise in the development and manufacture of sophisticated and transdermal drug delivery products to treat a variety of therapeutic areas.
“ProSolus is the new jewel in Mission’s crown as a manufacturing supplier,” said Pete Valko, chief operating officer of ProSolus Inc., who is adding this to his responsibilities as chief operating officer of BioComp Pharma. “To expand Mission’s offerings, ProSolus brings high-barrier-to-entry transdermal solutions and a top-notch manufacturing facility with its own research and development arms. Mission’s goal is to deliver this exceptional science and skill into customers’ hands through innovative and convenient products.”
ProSolus’ chief executive officer Juan Mantelle will continue to serve in an executive leadership role overseeing R&D as chief scientific officer.
“Juan Mantelle and the ProSolus team excel in the design aspects of transdermal products. It’s really an art more than a science,” said Terry Herring, president, commercial operations, Mission Pharmacal. “They have significantly improved the wearability of transdermal patches, creating more desirable, smaller sizes that stay in place while working effectively. This design strength combined with state-of-the-art manufacturing capabilities gives us vast potential to quickly deliver patient-friendly transdermal solutions.”
Five years ago, Mission partnered with ProSolus and Richmar Corp.to produce the LidoFlex Pain Relief Patch, which delivers a 4% concentration of lidocaine, the highest available without a prescription. The LidoFlex line includes assorted, extremity-specific sizes and shapes to provide localized pain relief without systemic or habit-forming medications.
“ProSolus is the new jewel in Mission’s crown as a manufacturing supplier,” said Pete Valko, chief operating officer of ProSolus Inc., who is adding this to his responsibilities as chief operating officer of BioComp Pharma. “To expand Mission’s offerings, ProSolus brings high-barrier-to-entry transdermal solutions and a top-notch manufacturing facility with its own research and development arms. Mission’s goal is to deliver this exceptional science and skill into customers’ hands through innovative and convenient products.”
ProSolus’ chief executive officer Juan Mantelle will continue to serve in an executive leadership role overseeing R&D as chief scientific officer.
“Juan Mantelle and the ProSolus team excel in the design aspects of transdermal products. It’s really an art more than a science,” said Terry Herring, president, commercial operations, Mission Pharmacal. “They have significantly improved the wearability of transdermal patches, creating more desirable, smaller sizes that stay in place while working effectively. This design strength combined with state-of-the-art manufacturing capabilities gives us vast potential to quickly deliver patient-friendly transdermal solutions.”
Five years ago, Mission partnered with ProSolus and Richmar Corp.to produce the LidoFlex Pain Relief Patch, which delivers a 4% concentration of lidocaine, the highest available without a prescription. The LidoFlex line includes assorted, extremity-specific sizes and shapes to provide localized pain relief without systemic or habit-forming medications.
